Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

74737 1534256234HCLSReviewPortugalAugust2018.pdf
Energy Boardroom

Type your email in the box below to read this content NOW:

Interview

Vivek Sharma – CEO, Piramal Pharma Solutions (PPS), India

Vivek Sharma, CEO of Piramal Pharma Solutions (PPS), one of the world’s leading CDMOs with a presence in North America, Europe, and Asia, provides insights into the main trends shaping the global demand for contract development and manufacturing services. He also highlights the company’s customer-centric business model, the strength of its global manufacturing footprint its M&A strategy, as well as how he aims to establish PPS as a best-in-class organization in terms of quality compliance.

The global CDMO market amounted to USD 65.8 billion in 2016 and is set to experience a sustained growth moving forward to eventually reach USD 85 billion by 2020. What do you identify as the main drivers behind this strong demand?

When looking at the macro environment, all Big Pharma companies want to increase the speed-to-market of their life-changing products while at the same time reduce development and manufacturing costs. They strive to apply this approach to an ever-increasing number of products in the pipeline but they do not hold the in-house capacity to reach this objective. In this context, they are left with no choice but to look for external partners that can enable a streamlined and faster go-to-market model and this is precisely where the CDMO industry enters the picture.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: